ProKidney (PROK) Stock Overview
A clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PROK Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
ProKidney Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$7.13 |
| 52 Week Low | US$0.46 |
| Beta | 1.8 |
| 1 Month Change | -24.24% |
| 3 Month Change | -21.88% |
| 1 Year Change | 108.41% |
| 3 Year Change | -80.83% |
| 5 Year Change | n/a |
| Change since IPO | -82.69% |
Recent News & Updates
Recent updates
Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation
Mar 03
2025 Will Be A Major Year For ProKidney's Rilparencel In CKD Treatment
Jan 31We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely
Nov 18We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate
Aug 12We Think ProKidney (NASDAQ:PROK) Can Afford To Drive Business Growth
May 12Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation
Nov 17ProKidney (NASDAQ:PROK) Is In A Strong Position To Grow Its Business
Mar 14ProKidney reports Q2 2022 results
Aug 11Shareholder Returns
| PROK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.4% | 2.3% | -0.3% |
| 1Y | 108.4% | 31.7% | 16.1% |
Return vs Industry: PROK exceeded the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: PROK exceeded the US Market which returned 16% over the past year.
Price Volatility
| PROK volatility | |
|---|---|
| PROK Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: PROK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PROK's weekly volatility has decreased from 75% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 231 | Bruce Culleton | prokidney.com |
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial.
ProKidney Corp. Fundamentals Summary
| PROK fundamental statistics | |
|---|---|
| Market cap | US$540.43m |
| Earnings (TTM) | -US$68.99m |
| Revenue (TTM) | US$893.00k |
Is PROK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROK income statement (TTM) | |
|---|---|
| Revenue | US$893.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$893.00k |
| Other Expenses | US$69.88m |
| Earnings | -US$68.99m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 100.00% |
| Net Profit Margin | -7,725.20% |
| Debt/Equity Ratio | 0% |
How did PROK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 14:20 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ProKidney Corp. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dina Ramadane | BofA Global Research |
| Yigal Nochomovitz | Citigroup Inc |
| Vamil Divan | Guggenheim Securities, LLC |